Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.

Christoph A Schatz Sabine Zitzmann-Kolbe Ingrid Moen Monika Klotz Shankari Nair Stefan Stargard Roger M Bjerke Katrine Wickstrøm Biseth Yuan Zeng Feng Bård Indrevoll Véronique Cruciani Jenny Karlsson Bernard Haendler Carsten H Nielsen Maria Z Alfsen Stefanie Hammer Hartwig Hennekes Alan S Cuthbertson Urs B Hagemann Aasmund Larsen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

These results provide a strong rationale to investigate 225Ac-pelgi in patients with prostate cancer. A clinical phase I study has been initiated (NCT06052306).

Keyphrases

prostate cancer
cancer therapy
radical prostatectomy
pet ct
clinical trial
drug delivery
pet imaging
cell therapy
computed tomography
bone marrow